Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | MAPK3 |
| Gene Name: | MAPK3 |
| Protein Full Name: | Mitogen-activated protein kinase 3 |
| Alias: | EC 2.7.11.24; ERK-1; ERT2; Insulin-stimulated MAP2 kinase; Kinase ERK1; MAP kinase 1; MAPK 1; MAPK1; MAPK3; Microtubule-associated protein kinase; Microtubule-associated protein-2 kinase; Mitogen-activated protein kinase 3; MK03; MNK1; P44erk1; P44-ERK1; P44mapk; P44-MAPK; PRKM3 |
| Mass (Da): | 43136 |
| Number AA: | 379 |
| UniProt ID: | P27361 |
| Locus ID: | 5595 |
| COSMIC ID: | MAPK3 |
| Gene location on chromosome: | 16p11.2 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20473 |
| Percent of cancer specimens with mutations: | 0.23 |
| Normal role description: | MAPK3 is ubiquitously expressed protein serine/threonine kinase involved in regulating cellular differentiation and proliferation in response to extracellular mitogens or growth factors. MAPK3 is activated by upstream signalling by monomeric G-proteins. MAPK3 activation leads to its translocation from the cytosol to the nucleus where it can target substrate proteins involved in cell cycle regulation; Cyclin D1, suppression of apoptosis; BCL2 and BAD, tumour supression; p53, cell migration; PAI-1, and MHCII mediated immune response; PPARg1. Dysfunction of MAPK3 expression and activity has been observed in a variety of cancers. Predominantly overexpression of MAPK3 or constitutive activation has been observed in cancer cell lines. Activation of MAPK3 does not appear to be due to mutations in the protein itself but rather aberrant signalling in upstream factors including Raf, Ras and epidermal growth factor receptor. MAPK3 may also have a role in promoting metastasis in invasive tumours. |